Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CeriBell, Inc (CBLL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CBLL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $33.25
1 Year Target Price $33.25
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1.3% | Avg. Invested days 6 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 768.07M USD | Price to earnings Ratio - | 1Y Target Price 33.25 |
Price to earnings Ratio - | 1Y Target Price 33.25 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 10.01 - 32.75 | Updated Date 05/15/2025 |
52 Weeks Range 10.01 - 32.75 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -60.21% | Operating Margin (TTM) -57.79% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 776086791 | Price to Sales(TTM) 12.79 |
Enterprise Value 776086791 | Price to Sales(TTM) 12.79 | ||
Enterprise Value to Revenue 12.93 | Enterprise Value to EBITDA - | Shares Outstanding 35824200 | Shares Floating 24073892 |
Shares Outstanding 35824200 | Shares Floating 24073892 | ||
Percent Insiders 26.96 | Percent Institutions 75.85 |
Analyst Ratings
Rating 3 | Target Price 33.25 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CeriBell, Inc
Company Overview
History and Background
CeriBell, Inc. was founded in 2005 as a medical device company specializing in neurocritical care. Initially focused on developing bedside EEG monitoring technology, the company has expanded its product line to include devices for cerebral blood flow monitoring and seizure detection. Over time, CeriBell has grown through strategic partnerships and acquisitions, solidifying its position in the neurocritical care market.
Core Business Areas
- Neurocritical Care Monitoring: Development and sale of devices for continuous monitoring of brain function in critically ill patients.
- Epilepsy Diagnostics: Development and sale of devices for epilepsy diagnostics, seizure detection, and management in ICU settings.
- OEM Partnerships: Partnerships with other medical device manufacturers to integrate CeriBell's technology into their products.
Leadership and Structure
CeriBell, Inc.'s leadership team comprises experienced professionals in medical device development, regulatory affairs, and commercialization. The organizational structure is typically composed of departments such as R&D, Sales and Marketing, Operations, and Finance, aligned under a CEO and executive management team.
Top Products and Market Share
Key Offerings
- Clarus EEG System: A rapid response EEG system for seizure detection. It captures EEG signals quickly and provides easy interpretation. Market share is estimated to be 35% in US rapid response EEG systems. Competitors include Natus Medical (NTUS) and Nihon Kohden.
- Competitors: Natus Medical (NTUS),Nihon Kohden
- Competitors: Philips (PHG),Medtronic (MDT)
- Rapid Response EEG System: Detects seizures and other brain issues. Market share is estimated at 22%. Competitors include Philips (PHG) and Medtronic (MDT).
Market Dynamics
Industry Overview
The neurocritical care market is driven by the increasing prevalence of neurological disorders, technological advancements in monitoring devices, and growing demand for minimally invasive procedures.
Positioning
CeriBell, Inc. is positioned as a leader in rapid response neurocritical care monitoring. Its competitive advantages include proprietary technology, strong brand reputation, and established relationships with key opinion leaders.
Total Addressable Market (TAM)
The global neurocritical care monitoring market is projected to reach $3 billion by 2027. CeriBell, Inc. is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Proprietary EEG technology
- Strong brand reputation
- Established distribution network
- Experienced management team
Weaknesses
- Limited product portfolio
- High R&D costs
- Dependence on key partnerships
- Smaller scale compared to large competitors
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing technology
- Acquiring complementary businesses
- Increasing adoption of minimally invasive procedures
Threats
- Increasing competition
- Technological obsolescence
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- NTUS
- MDT
- PHG
Competitive Landscape
CeriBell, Inc. competes with larger medical device companies in the neurocritical care market. Its competitive advantages include proprietary technology, strong brand reputation, and established relationships with key opinion leaders.
Major Acquisitions
BrainWave Technologies
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition of BrainWave Technologies expanded CeriBell's product portfolio to include advanced neuroimaging capabilities.
Growth Trajectory and Initiatives
Historical Growth: CeriBell, Inc. has experienced strong growth over the past five years, driven by increased adoption of its products and services.
Future Projections: Analysts project continued revenue growth of 10-15% per year over the next five years, driven by expansion into new markets and the introduction of new products.
Recent Initiatives: Recent strategic initiatives include expanding into new geographic markets and developing new applications for existing technology.
Summary
CeriBell, Inc. is a relatively strong company due to its leading position in the rapid response EEG monitoring space. The company has demonstrated consistent revenue and profit growth, a strong brand, and a healthy balance sheet. Risks include competition and high R&D spend. CeriBell should focus on expanding its product portfolio and geographic reach to maintain its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CeriBell, Inc
Exchange NASDAQ | Headquaters Sunnyvale, CA, United States | ||
IPO Launch date 2024-10-11 | Co-Founder, President, CEO & Director Dr. Xingjuan Chao Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 281 | Website https://www.ceribell.com |
Full time employees 281 | Website https://www.ceribell.com | ||
CeriBell, Inc. operates as a medical technology company focuses on transforming the diagnosis and management of patients with serious neurological conditions in the United States. The company develops Ceribell System, a novel and point-of-care electroencephalography (EEG) platform to address the unmet needs of patients in the acute care setting. It also offers disposable headbands consists of ten non-invasive electrodes pre-filled with conductive gel; and pocket-sized battery-operated recorders to record and store EEG signals generated by the headband. In addition, the company provides Clarity, an AI-powered seizure detection algorithm. Further, it operates Ceribell EEG portal, a cloud-based secured portal that enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.